Cancer-associated venous thromboembolism: advances and clinical challenges in anticoagulation therapy

Venous thromboembolism is one of the most frequent and severe complications of cancer, with significant im­pact on the prognosis and survival of oncology patients. As on­co­lo­gic therapies advance, the risk of deep vein throm­bo­sis and pulmonary embolism increases, requiring con­ti­nuous reas­ses­sment of anticoagulant strategies. This article ana­lyzes the recommendations from major international guide­lines (ESC, ASH, ACCP, IC-OS) on anticoagulation in oncology pa­tients, with emphasis on personalized therapy and the de­li­cate balance between thrombotic and hemorrhagic risks.